Chengdu Olymvax Biopharmaceuticals Inc.
688319
Rank in Stocks
#6676
Chengdu Olymvax Biopharmaceuticals Inc. specializes in the research,... Chengdu Olymvax Biopharmaceuticals Inc. specializes in the research, development, and distribution of vaccines. Their current product portfolio includes immunizations against tetanus, a severe and often fatal infectious disease that damages the nervous system due to toxins produced by Clostridium tetani, alongside a vaccine for Haemophilus influenzae type b. Beyond their existing offerings, the company is actively advancing new vaccine candidates targeting Staphylococcus aureus, a prevalent bacterium responsible for both hospital-acquired and community infections, and illnesses associated with Group A streptococcus. This enterprise was established in 2009 and operates from its base in Chengdu, China.
Share Price
$4.00
Last synced: 2026-11-13
Market Cap
$1.62B
Change (1 day)
-3.55%
Change (1 year)
22.75%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Chengdu Olymvax Biopharmaceuticals Inc. (688319)
Category
Healthcare
Operating Margin for Chengdu Olymvax Biopharmaceuticals Inc. (688319)
Operating Margin as of November 2026 TTM: 8.19%
According to Chengdu Olymvax Biopharmaceuticals Inc.'s latest financial reports, its current operating margin (TTM) is 8.19%. At the end of 2025 the company had an operating margin of 4.38%.
Operating Margin history for Chengdu Olymvax Biopharmaceuticals Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 8.19% | 86.99% |
| 2025 | 4.38% | 20.99% |
| 2024 | 3.62% | 483.87% |
| 2023 | 0.62% | -91.84% |
| 2022 | 7.60% | -63.55% |
| 2021 | 20.85% | 101.45% |
| 2020 | 10.35% | -155.89% |
| 2019 | -18.52% | -33.41% |
| 2018 | -27.81% | 134.88% |
| 2017 | -11.84% | -99.97% |
| 2016 | -35,129.41% | 161.91% |
| 2015 | -13,412.64% | -25.20% |
| 2014 | -17,930.15% | 276.92% |
| 2013 | -4,757.02% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -123.86% |
US
|
|
| 33.87% | -95.86% |
US
|
|
| -116.04% | -114.17% |
US
|
|
| 25.57% | -96.88% |
AU
|
|
| 31.23% | -96.19% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin
What is Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin?
Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin is 8.19%, as of Nov 2026.
What was Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin in 2025?
In 2025, Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin was 4.38%, compared with 3.62% in 2024.
How has Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin changed since 2020?
From 2020 to 2025, Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin was highest in 2021 (20.85%) and lowest in 2023 (0.62%).
How does Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin compare with similar companies?
Chengdu Olymvax Biopharmaceuticals Inc.'s operating margin (8.19%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.